J2281, Injection, moxifloxacin (fresenius kabi), not therapeutically equivalent to
HCPCS/CPT
Prior Authorization
No Prior Auth Required
Code is covered without prior authorization (high confidence)
Medicare Pricing
Work RVU
0.00
Facility
N/A
Non-Facility
N/A
Key Coverage Criteria
- A course of up to 4 weeks of intravenous (IV) antibiotic therapy is consideredmedically necessaryfor individuals with Lyme disease meetingBOTHcriteria AandB below:
- The condition to be treated isONEof the following (1, 2,or3):Myocarditis associated with any of the following:First-degree heart block when the PR interval is prolonged to 300 milliseconds or greater;orSecond-degree atrioventricular block;orThird-degree atrioventricular block;orPersistent or recurrent joint swelling (that is, arthritis) after an initial 1 month trial of oral antibiotics;orAcute or chronic neurological disease affecting the central or peripheral nervous system, includingANYof the [...]
- Myocarditis associated with any of the following:First-degree heart block when the PR interval is prolonged to 300 milliseconds or greater;orSecond-degree atrioventricular block;orThird-degree atrioventricular block;or
- First-degree heart block when the PR interval is prolonged to 300 milliseconds or greater;or
- Second-degree atrioventricular block;or
- Third-degree atrioventricular block;or
1 Active Policy
ANTHEM-CG-MED-98, CG-MED-98 Parenteral Antibiotics for the Treatment of Lyme Disease
Related Codes
Have a follow-up question?
Ask Verity about documentation requirements, denial risks, or coverage in your state.